STOCKHOLM, SWEDEN--(Marketwire - March 30, 2012) -
Sobi has amended its share purchase agreement regarding the acquisition in
of the pharmaceutical company Arexis AB, which included a number of
According to the amended agreement, Sobi will not have any remaining
obligations towards the sellers. In addition, Sobi will make a payment to
all future milestone obligations for the Kiobrina program.
Under the amended agreement, Sobi will pay the sellers a total of SEK 77 M,
which SEK 43 M relates to the future milestone obligations for the Kiobrina
program. Sobi will pay SEK 36 M at signing of the amended agreement, SEK 20
2013, and SEK 21 M in 2014.
The payment of SEK 43 M referring to the milestones for Kiobrina will be
included in intangible assets in Sobi's balance sheet. An amount of SEK 34
will be charged against operating income as a non-recurring item in the
quarter of 2012.
As stated in Sobi's annual and quarterly reports, the sellers of Arexis had
initiated arbitration as well as an expert determination procedure
their claims, and both proceedings will now be withdrawn avoiding a
and expensive legal process.
Kiobrina is a recombinant human bile salt stimulated lipase (rhBSSL) in
III development as an enzyme replacement therapy to improve growth in
infants who receive pasteurized breast milk or infant formula.
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to
innovative therapies and services to improve the health of rare disease
and their families. The product portfolio comprises about 45 marketed
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK
billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ
Stockholm. More information is available at www.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information
released for public distribution on 30 March 2012 at 08.30 CET.
Sobi press release March 30, 2012 in pdf version:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE